Krystal Biotech, Inc. cotiza a 332.07 USD y tiene una capitalización bursátil de $9.8B. En los últimos 12 meses ha facturado $440M con un margen de flujo de caja libre del 48.5%. Cotiza a 38.1 veces su flujo de caja libre (P/FCF) y a un PER de 40.7. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epiderm…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $1.79 | $1.83 | $1.70 |
| Estimado | $1.98 | $1.91 | $1.42 | $1.61 |
| Sorpresa | — | -6.3% | +28.9% | +5.6% |
| Métrica | KRYS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 41.5% | -38.6% | +80.1% |
| Net Margin | 52.6% | -33.6% | +86.2% |
| FCF Margin | 48.5% | -13.9% | +62.4% |
| ROE | 16.8% | -40.4% | +57.2% |
| ROA | 15.4% | -32.0% | +47.4% |
| Current Ratio | 9.95 | 2.84 | +7.11 |
| Debt / Equity | — | 0.28 | — |